Irradiation-Inactivated Staphylococcus Compositions With Epitope Protection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The increasing prevalence of antibiotic-resistant bacteria, particularly Methicillin-resistant Staphylococcus aureus (MRSA), poses a significant challenge in clinical treatment, with no effective vaccines available to prevent infections and limited therapeutic countermeasures.

Innovation Solution

Development of irradiation-inactivated Staphylococcus aureus compositions, using antioxidants like manganese-peptide-orthophosphate complexes to protect immunogenic epitopes during irradiation, followed by analysis to identify correlates of protective immunity, enabling the creation of subunit vaccines.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemical inactivation methods are used to prepare staphylococcal vaccine compositions, then the bacteria are effectively inactivated, but damage occurs to protective epitopes reducing immunogenicity

Engineering Contradiction:

Improvebacterial inactivation efficacyVSAvoidepitope integrity

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent transitions from chemical inactivation parameters to physical irradiation parameters (gamma radiation at 25-50 kGy, UV-C at 4-10 mW/cm² for 10-60 seconds), fundamentally changing the inactivation mechanism to avoid chemical damage to epitopes while maintaining reliable bacterial inactivation

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces antioxidants (manganese-peptide-orthophosphate complexes, vitamin C, superoxide dismutase) as intermediary substances that protect epitopes from oxidative damage during irradiation, mediating between the inactivation process and the epitopes to prevent harm

Inventive Principle:

Principle #24Intermediary (Mediator)

2Manufacturing precision

If irradiation is used to inactivate staphylococcus, then epitope damage is reduced, but reactive oxygen species can still damage exterior macromolecules

Engineering Contradiction:

Improveepitope integrityVSAvoidoxidative damage from reactive oxygen species

Core Design Contradiction:

Manufacturing precisionVSObject-affected harmful factors

Solution Approach 1:

Antioxidants serve as intermediary substances that absorb and neutralize reactive oxygen species generated during irradiation, protecting exterior macromolecules and epitopes from oxidative damage while allowing the irradiation inactivation process to proceed

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies antioxidants before and during irradiation to pre-establish protective mechanisms against reactive oxygen species, cushioning the epitopes and macromolecules from potential oxidative damage before it occurs

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method preserves immunogenicity and stimulates protective immunity, allowing for the development of more effective vaccines against MRSA by reducing damage to protective epitopes and identifying key bacterial proteins for subunit immunogens.

Implementation Method 1

irradiation-inactivated (such as by gamma ray, x-ray, and/or UV (e.g., UVC)) staphylococcus

Methodology Applied

Scientific EffectIrradiation: Radiation

Implementation Method 2

inclusion of antioxidants such as manganese-peptide-orthophosphate (MDP) complexes may protect exterior macromolecules from damage during the radiation-inactivation process

Methodology Applied

Scientific EffectOxidation protection: Oxidation

Data Source

PatentUS20250295749A1Inactivated staphylococcus compositions and methods of making and using the same

Publication Date: 2025.09.25 BIOLOGICAL MIMETICS

AI summary

Presented herein are inactivated Staphylococcal bacterial immunogens. Also described herein are compositions including Staphylococcal immunogens. Methods for preparing and using the same are also described. Immunogens may enable a host immune response that can protect the host from infection and/or disease. Differential analysis of antigens that stimulate protective (immunogenic) and non-protective immunity can be used to identify correlates of protection that can be developed as subunit vaccine candidates.